User login
Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.
Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P = .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P = .673).
Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.
Disclosures: The study received no funding. The authors declared no conflicts of interest.
Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002
Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.
Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P = .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P = .673).
Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.
Disclosures: The study received no funding. The authors declared no conflicts of interest.
Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002
Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.
Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P = .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P = .673).
Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.
Disclosures: The study received no funding. The authors declared no conflicts of interest.
Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002